Beijing-based InnoCare Pharma (HKEX: 09969) has entered a strategic research collaboration and license agreement with Eli Lilly and Company (NYSE: LLY)... H. Lundbeck A/S will relocate its US ...
FDA approves Welireg and Lenvima combination for advanced renal cell carcinoma. Learn about this breakthrough treatment for ...
BigHat Biosciences secures $75M Series C to advance AI-designed protein therapeutics. Total funding reaches $223M. Discover ...
Addex Therapeutics regains full global rights to GABAB PAM portfolio from Indivior. Collaboration termination follows ...
XtalPi files FDA IND application for KQTD-126, a gut-restricted pan-TRK inhibitor for chronic intestinal pain. First-in-class ...
Waltham, Massachusetts-based Pretzel Therapeutics announced receipt of US FDA Fast Track Designation for PX578, a central nervous system-penetrant small molecule activator of mitochondrial DNA ...
Celldex reports positive Phase 3 results for barzolvolimab in chronic urticaria, meeting primary endpoints. Read the ...
Siemens Healthineers and Novo collaborate to expand non-invasive blood-based testing for MASLD and MASH. Learn about this healthcare partnership.
US Treasury drafts rules allowing pharmaceutical companies to license drugs from Chinese biotech firms. Learn how new regulations affect US-China ...
Viking's VK2735 sustains 97% weight loss with monthly injections. Discover how this GLP-1/GIP agonist offers flexible ...
Johnson & Johnson's Caplyta (lumateperone) shows significant efficacy in bipolar I disorder mania. Phase III trial results presented at Psych Congress 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results